The following are key points to remember from a state-of-the-art review on cardiovascular (CV) risk in prostate cancer (PC): ...

Multimodality imaging can identify papillary muscles that are the source of arrhythmias. Increased echogenicity, gadolinium enhancement, and calcifications on papillary muscles can indicate site of ...

Early increases in CRP during immune checkpoint inhibitor (ICI) therapy are linked to a higher risk of venous thromboembolism (VTE). CRP trajectories could serve as biomarkers for assessing VTE risk ...

The following are key points to remember from a review on nonsurgical management of chronic venous insufficiency (CVI): ...

Chlorthalidone is not superior to hydrochlorothiazide in preventing kidney disease progression in patients with hypertension. Chlorthalidone causes slightly more hypokalemia than hydrochlorothiazide.

There are several companies that are not affiliated with the American College of Cardiology that are posting registration and housing information for ACC.24. To protect your information, please only ...

Highlighted text has been updated as of December 20, 2024. The SURMOUNT-1 trial showed that among patients with obesity, once-weekly tirzepatide reduced body weight substantially as compared to ...

Highlighted text has been updated as of December 20, 2024. The SUMMIT trial showed that among obese patients with HFpEF, once weekly subcutaneous tirzepatide was superior to placebo in improving the ...

In this week’s View, Dr. Eagle looks at the use of waist-high compression tights in patients with postural orthostatic tachycardia syndrome (POTS). He then discusses a consensus statement on platelet ...

ACC Online Courses offer the cardiovascular community a collection of resources and newly developed, evidence-based educational activities across topics such as lipid management, valvular heart ...

Join a community dedicated to innovative cardiovascular care, where every role contributes to our mission of transforming heart health. Explore opportunities that not only advance your career but also ...

The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...